Secondary market MindMed (NEO: MMED) announced that they have entered into a clinical trial agreement with Maastricht University to undertake a phase 2a clinical trial of lysergic acid diethylamide (LSD) in adult patients with attention deficit hyperactivity disorder (ADHD).
As per the agreement, Maastricht University will provide facilities and personnel for the Phase 2a proof of concept clinical trial for MindMed’s multicenter, randomized, double-blind, placebo-controlled safety trial. and the effectiveness of low-dose LSD as a treatment for ADHD in adults. .
The company will now move to an LSD microdosing program with Dr Kuypers and the Liechtenstein laboratory at the University Hospital Basel. They are currently in the regulatory ethics submission process in the Netherlands and plan to start the Phase 2a clinical trial by the end of the year. In order to create a portfolio of clinical trials investigating the use of subperceptual amounts of psychedelics for medical purposes, the company has created a microdosing division.
MindMed stock closed today up 3c to 60c.
Information for this briefing was found via Sedar and MindMed. The author has no title or affiliation related to this organization. Not a buy or sell recommendation. Always do additional research and consult a professional before purchasing a title. The author does not hold any license.
SmallCapSteve started blogging in the winter of 2009. During this time, it was able to spot many takeover candidates and pick a variety of stocks that generated returns in excess of 200%. Today, he consults with microcapsule companies to help them with financial market strategy and focuses on industries such as cannabis, tech and small mining.